Infinity Pharmaceuticals Inc. in Cambridge said today that Adelene Q. Perkins, its president and chief business officer, will become CEO on Jan. 1.
The company said Perkins will succeed founder, chairman and CEO Steven Holtzman. Holtzman started Infinity in 2001, and Perkins has been with the company since 2002. Perkins will join the board of directors, and Holtzman will remain with the company as executive chairman of the board.
Perkins became president of the company in October, 2008. Before she joined Infinity, according to a company release, she served at the vice president level at TransForm Pharmaceuticals and Genetics Institute. Perkins began her career at the consultant firm Bain & Company. She holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from Villanova University.